BioLineRX is planning a listing on the NASDAQ
Jerusalem, July 11, 2010. The Company hereby announces that, on July 11, 2010, the Company’s Board of Directors formally approved the process of registration with the U.S. Securities and Exchange Commission of an offering of the Company’s shares and a simultaneous listing of its securities on the NASDAQ. The Company has commenced the confidential offering process available to it in the U.S. as a foreign private issuer and intends to file its next amendment to the registration statement publicly.
The timing, amount and structure of the offering have not yet been determined.
It should be noted that this Immediate Report does not constitute a public offering or an inducement to purchase shares of any kind.
The Company’s intentions to offer its shares to the public in the US, as aforementioned, is considered forward-looking information, as defined in the Securities Laws, and is based on current estimates and assessments by the Company. The realization as expected, in part or in whole, of such information may be affected by risk factors that are not possible to estimate in advance and are not in the Company’s control, including factors that relate to the Company’s operations specifically, as well as factors related to conditions of the US capital markets in general.
